Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9457916 | 1.00 | ESR1 (0.34) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL9645607 | 0.93 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL9645615 | 0.93 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL9645601 | 0.93 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL86980 | 0.85 | — | — | |
| SCHEMBL61830 | 0.85 | — | — | |
| SCHEMBL10867021 | 0.82 | — | — | |
| SCHEMBL1414182 | 0.80 | ESR2 (0.38) | ESR2 | |
| Water SCHEMBL9548508 | 0.80 | ESR1 (0.44) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL12246837 | 0.78 | KMT2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-5238602-A | Electrooptical cells | HOFFMANN LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0168683-B1 | LIQUID CRYSTALS WITH ALKENYL OR ALKENYLOXY GROUPS | F. HOFFMANN-LA ROCHE AG (CH) | 1990-11-28 | — | — | EP | disclosed |
| EP-0167912-B1 | LIQUID CRYSTAL MIXTURES CONTAINING COMPOUNDS WITH A 4-ALKENYL OR 2Z-ALKENYL LATERAL CHAIN | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-03 | — | — | EP | disclosed |
| US-4776973-A | LIQUID CRYSTAL ELECTROOPTICS DISPLAY DEVICE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-10-11 | — | — | US | disclosed |
| US-4709030-A | 4-ALKENYL OR 2Z-ALKENYL POLYPHENYL COMPOUNDS; ELECTRO-OPTICS | HOFFMANN-LA ROCHE INC. (US) | 1987-11-24 | — | — | US | disclosed |
| US-4621901-A | ELECTROOPTICS | HOFFMANN-LA ROCHE INC. (US) | 1986-11-11 | — | — | US | disclosed |
| EP-0168683-A2 | Liquid crystals with alkenyl or alkenyloxy groups | F. HOFFMANN-LA ROCHE AG (CH) | 1986-01-22 | — | — | EP | disclosed |
| EP-0167912-A2 | Liquid crystal mixtures containing compounds with a 4-alkenyl or 2Z-alkenyl lateral chain | F. HOFFMANN-LA ROCHE AG (CH) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | ESR1 3581/4885ESR2 2501/4885CYP3A4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.